Phase 4
N=78
MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Bottom Line
View on ClinicalTrials.gov: NCT00956631 ↗Enrolled (actual)
78
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.21 units on a scale — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Interlaminar Decompression (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vertos Medical, Inc.
- Primary completion
- Apr 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). |
3.21 | <0.0001 sig |
Summary
This is a multi-center, prospective, clinical study to assess the clinical application and outcomes of MILD® Interlaminar Decompression in patients with symptomatic lumbar spinal stenosis.
Eligibility Criteria
Inclusion Criteria
- Symptomatic Lumbar Spinal Stenosis (LSS) primarily caused by dorsal element hypertrophy.
- Prior failure of conservative therapy.
- Radiologic evidence of LSS (L3-L5), Ligamentum flavum > 2.5mm, confirmed by pre-op MRI and/or CT.
- Central canal cross sectional area ≤ 100 square mm.
- Anterior listhesis ≤ 5.0mm.
- Able to walk at least 10 feet unaided before being limited by pain.
- Available to complete 12 weeks of follow-up.
- Consistent with the intended labeling statement for use.
- Able to use all package components to perform the procedure.
- A signed Informed Consent Form is obtained from the patient.
Exclusion Criteria
- Prior surgery at intended treatment level.
- History of recent spinal fractures with concurrent pain symptoms.
- Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).
- Significant / symptomatic disk protrusion or osteophyte formation.
- Excessive / symptomatic facet hypertrophy.
- Bleeding disorders and/or current use of anti-coagulants.
- Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.
- Epidural steroids within prior three weeks.
- Inability of the patient to lie prone for any reason with anesthesia support (e.g. chronic obstructive pulmonary disease (COPD), obesity, etc.).
- Any potential wound healing pathologies that may compromise outcomes, including diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe COPD.
- Dementia and/or inability to give informed consent.
- Pregnancy.
- Intended treatment that is defined by the product labeling contraindications.
- On Workman's Compensation or considering litigation associated with back pain.
Data sourced from ClinicalTrials.gov (NCT00956631). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.